Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
SENP1 encodes a cysteine protease that specifically targets members of the small ubiquitin-like modifier (SUMO) protein family. Additionally we are shipping SENP1 Proteins (4) and SENP1 Kits (3) and many more products for this protein.
Showing 10 out of 100 products:
Mouse (Murine) Polyclonal SENP1 Primary Antibody for WB - ABIN1881788
Bawa-Khalfe, Cheng, Lin, Ittmann, Yeh: SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. in The Journal of biological chemistry 2010
Show all 5 references for ABIN1881788
Human Polyclonal SENP1 Primary Antibody for WB - ABIN388043
Gong, Millas, Maul, Yeh: Differential regulation of sentrinized proteins by a novel sentrin-specific protease. in The Journal of biological chemistry 2000
Show all 3 references for ABIN388043
Human Polyclonal SENP1 Primary Antibody for IHC (p), WB - ABIN388042
Chen, Chen: MDM2-ARF complex regulates p53 sumoylation. in Oncogene 2003
Show all 3 references for ABIN388042
Human Polyclonal SENP1 Primary Antibody for EIA, WB - ABIN356750
Long, Burke: Interferon production by double-stranded RNA: a comparison of induction by reovirus to that by a synthetic double-stranded polynucleotide. in The Journal of general virology 1971
Show all 2 references for ABIN356750
Human Polyclonal SENP1 Primary Antibody for WB - ABIN2786045
Ohbayashi, Kawakami, Muromoto, Togi, Ikeda, Kamitani, Sekine, Honjoh, Matsuda: The IL-6 family of cytokines modulates STAT3 activation by desumoylation of PML through SENP1 induction. in Biochemical and biophysical research communications 2008
XSENP1a and XSENP1b are sumo-specific proteases that inhibit normal head formation by inhibiting Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling.
SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1alpha (show HIF1A Antibodies)
SENP1 expression has strong prognostic impact in a molecularly defined subset of cancers. This is per se not surprising as the biologic impact of each individual molecular event is likely to be dependent on its cellular environment.
SENP1 was expressed in human islets, and its mRNA level was unchanged in islets from donors with T2D. In cultured islets, overexpressed SENP1-GFP colocalized with secretory granules at the plasma membrane
SENP1 uses remote substrate binding for conformational flexibility and activation
SENP1 up-regulation in diseased heart is mediated via calcineurin (show PPP3CA Antibodies)-NFAT (show NFATC1 Antibodies)/MEF2C (show MEF2C Antibodies)-PGC-1alpha (show PPARGC1A Antibodies) pathway.
results provide independent evidence in support of a role for SENP1 in chronic mountain sickness in individuals of Quechua ancestry and suggest the SENP1 and ANP32D (show ANP32D Antibodies) signatures of selection are in tight linkage disequilibrium (LD).
Over-expression of small ubiquitin-like modifier (show SUMO1 Antibodies) proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer.(
low expression of miR (show MLXIP Antibodies)-145 was correlated with high expression of SENP1 in Prostate cancer cell line and the SENP1 3'-untranslated region was a regulative target of miR (show MLXIP Antibodies)-145 in vitro.
results delineate a key role for Senp1in IL-6 (show IL6 Antibodies) induced proliferation and survival of MM cells, suggesting it may be a potential new therapeutic target in MM
SENP1 deficiency exacerbates ischemia-reperfusion injury in cardiomyocytes via a HIF1alpha (show HIF1A Antibodies)-dependent pathway.
SENP1 deletion in adipocytes causes Type 1 diabetes mellitus via enhanced SUMOylation of NEMO (show IKBKG Antibodies), leading to increased NF-kappaB (show NFKB1 Antibodies) activity, cytokine production and pancreatic inflammation.
results of the present study are of both theoretical and therapeutic significance to explore the potential roles of SENP1 under IH condition and elucidated the mechanisms underlying microglial survival and activation
A role for islet SENP1 as a regulator of in vivo glucose homeostasis was demonstrated by the tissue-selective and inducible knockout of this enzyme.
SENP1 enhances adipogenesis through de-SUMOylation of Sharp-1 (show BHLHE41 Antibodies), which then releases Sharp-1 (show BHLHE41 Antibodies) repression of PPARgamma (show PPARG Antibodies) expression and adipocyte differentiation. These results reveal SENP1 as a novel regulator in adipogenesis.
Senp1 Is the Primary Activity for Desumoylation of Sumo1 (show SUMO1 Antibodies)-Modified Proteins.
SENP1 is a specific SUMO protease to regulate SUMOylation status of PGC-1alpha (show PPARGC1A Antibodies).
SENP1 is essential for cell survival during endoplasmic reticulum stress.
SENP1 is essential for the development of early T and B cells.
This gene encodes a cysteine protease that specifically targets members of the small ubiquitin-like modifier (SUMO) protein family. This protease regulates SUMO pathways by deconjugating sumoylated proteins. This protease also functions to process the precursor SUMO proteins into their mature form. Alternate splicing results in multiple transcript variants.
sentrin-specific protease 1
, SUMO1/sentrin specific peptidase 1
, sentrin/SUMO-specific protease 1
, similar to Sentrin-specific protease 1 (Sentrin/SUMO-specific protease SENP1)
, sentrin/SUMO-specific protease SENP1
, sentrin specific protease 1b
, SUMO1/sentrin specific protease 1
, SUMO-1 protease 2
, SUMO-specific protease U1p1
, sentrin specific protease 1a
, Sumo1/sentrin/SMT3 specific peptidase 1